Patient Care Research Database News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mental Health Risks Higher Among Young People With IBD

Beyond anxiety and depression, researchers report children and young adults with inflammatory bowel disease are at higher risk for developing a wide range of mental health disorders.

United kingdomCity ofNick kennedySara mesilhyRichardk russellPatient care research databaseRoyal college of physiciansColitis organisationRoyal devon university healthcareRoyal hospitalSick childrenEuropean crohnOptimum patient care research databaseProactive psychologistsRoyal collegePfizer russell

Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study

Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSouth koreaPatient care research databaseEuropean respiratory societyAmerican thoracic societyGlobal initiative for asthmaOptimum patient care research databaseBritish thoracic difficult asthmaAsthma allergyEnglj medAllergy clin immunolRheum dis

Type 2 Inflammatory Disease Burden and Impact on Asthma

Type 2 Inflammatory Disease Burden and Impact on Asthma
dovepress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dovepress.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesPatient care research databaseAmerican thoracic societyGlobal initiative for asthmaAssociation between typeGlobal initiativeOptimum patient care research databaseOptimum patient careExisting typeBurden scoreExacerbation burdenBetween typeDisease burdenMedical encountersPriori conditions related

Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma

Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma Amgen and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroid dose, without loss of asthma control, with tezepelumab compared to placebo. The 48-week trial assessed the efficacy and safety of the potential new medicine tezepelumab compared to placebo in 150 severe asthma patients who required maintenance use of oral … Amgen (NASDAQ:AMGN) and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroid (OCS) dose, without loss of asthma control, with tezepelumab compared to placebo.

Puerto ricoUnited statesUnited kingdomLymphopoietin isoformsMegan foxTrish rowlandDavidm reeseExchange commissionClinical trial programPatient care research databaseDrug administrationBeigene ltdBreakthrough therapy designationAstrazeneca collaborationNorth americaTrial program